Wells Fargo Maintains Overweight on Biogen, Lowers Price Target to $343
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an 'Overweight' rating on Biogen (NASDAQ:BIIB) but lowered the price target from $350 to $343.
August 07, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Biogen's price target has been lowered by Wells Fargo from $350 to $343, though the 'Overweight' rating is maintained.
The lowering of the price target by Wells Fargo could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Overweight' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100